Get started
Author

Young Su Noh

Observed names: Y.S. Noh, Young S. Noh, Young su Noh
ORCID: 0000-0002-4204-2503
Observed ORCID: 0000-0002-4204-2503
OpenAlex ID: A5082149375
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma
2021 · Ivana Yen, Frances Shanahan, et al. · Nature · 136
Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study.
2019 · Tae Won Kim, Jeeyun Lee, et al. · Journal of Clinical Oncology · 48
Olmutinib in T790M‐positive non–small cell lung cancer after failure of first‐line epidermal growth factor receptor‐tyrosine kinase inhibitor therapy: A global, phase 2 study
2021 · Keunchil Park, Pasi A. Jӓnne, et al. · Cancer · 41
PDF
Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial
2019 · Dong-Wan Kim, Dae Ho Lee, et al. · Lung Cancer · 34
A phase Ib trial of belvarafenib in combination with cobimetinib in patients with advanced solid tumors: Interim results of dose-escalation and patients with NRAS-mutant melanoma of dose-expansion.
2021 · Sang Joon Shin, Jeeyun Lee, et al. · Journal of Clinical Oncology · 31
A safety, pharmacokinetic, pharmacogenomic and population pharmacokinetic analysis of the third‐generation EGFR TKI, olmutinib (HM61713), after single oral administration in healthy volunteers
2019 · Young Su Noh, Seonghae Yoon, et al. · Basic & Clinical Pharmacology & Toxicology · 14
Exploring Molecular Genetic Alterations and RAF Fusions in Melanoma: A Belvarafenib Expanded Access Program in Patients with RAS/RAF -Mutant Melanoma
2024 · Kyoo Hyun Kim, Sungmin Cho, et al. · The Oncologist · 12
Development of a simple and sensitive HPLC-MS/MS method for determination of diazepam in human plasma and its application to a bioequivalence study
2017 · Do-Hyung Kim, Ji-Yoon Cho, et al. · Translational and Clinical Pharmacology · 11
HM43239, a Novel Potent Small Molecule FLT3 Inhibitor, in Acute Myeloid Leukemia (AML) with FMS-like Tyrosine Kinase 3 (FLT3) Mutations: Phase 1 /2 Study
2019 · Naval G. Daver, Kyoo Hyung Lee, et al. · Blood · 6
Caffeoyloxy-5,6-dihydro-4-methyl-(2H)-pyran-2-one isolated from the leaves of Olinia usambarensis attenuates LPS-induced inflammatory mediators by inactivating AP-1 and NF-κB
2019 · Shin-Young Kang, Ji-Sun Shin, et al. · Chemico-Biological Interactions · 4
First-in-human study of HM95573, a novel oral RAF inhibitor, in patients with solid tumors.
2016 · Yong Sang Hong, Jeeyun Lee, et al. · Journal of Clinical Oncology · 4
HM43239, a Novel Small Molecule Inhibitor of FLT3, in Acute Myeloid Leukemia (AML) with and without FMS-like Tyrosine Kinase 3 (FLT3) Mutations: Phase 1/2 Study
2020 · Naval Daver, Kyoo Hyung Lee, et al. · Blood · 3
A phase 2 study to assess the safety and efficacy of FLX475 (tivumecirnon) combined with pembrolizumab in patients with advanced or metastatic gastric cancer.
2025 · Do-Youn Oh, Min-Hee Ryu, et al. · Journal of Clinical Oncology · 2
661MO Anti-tumor activity of belvarafenib in combination with cobimetinib in patients with metastatic solid tumors harboring BRAF fusions or BRAF class II/III mutation
2023 · T.W. Kim, J. Lee, et al. · Annals of Oncology · 2
PDF
Pharmacokinetics and bioequivalence of two fenofibrate choline formulations in healthy subjects under fed and fasted condition
2019 · Ji-Min Park, Soo-In Chae, et al. · International Journal of Clinical Pharmacology and Therapeutics · 2
976P HM97662, a novel EZH1/2 dual inhibitor, in patients with advanced or metastatic solid tumors: Initial results from a first-in-human phase I study
2025 · B. Keam, K. Kim, et al. · Annals of Oncology · 1
698 A phase I, open-label, multinational, multicenter, dose escalation and expansion study of BH3120 (4–1BB x PD-L1 BsAb) in patients with advanced or metastatic solid tumors
2024 · Dong-Wan Kim, Hye Ryun Kim, et al. · Journal for ImmunoTherapy of Cancer · 1
539 A Phase I, open-label, multicenter, dose escalation and expansion study of HM16390, as a single agent and in combination with pembrolizumab, in patients with advanced or metastatic solid tumors
2025 · Jong Chul Park, Bhumsuk Keam, et al. · Journal for ImmunoTherapy of Cancer
PDF
684TiP A phase I, open-label, multicenter, dose escalation and expansion study of HM97662 (EZH1/2 dual inhibitor) as a single agent in patients with advanced or metastatic solid tumors
2024 · B. Keam, J-H. Ahn, et al. · Annals of Oncology
PDF
Abstract A012: Emergence of MEK1 mutations in RAF or RAS-mutant solid tumors following treatment with a combination of selective type II RAF inhibitor belvarafenib and MEK inhibitor cobimetinib
2024 · Stephanie Hilz, Marissa Chen, et al. · Cancer Research
Works count: 20
Citation count: 352
H-index: 8
I10-index: 8
Year
Topic
Type